This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

reputable news agency

proofread

AstraZeneca buys US biotech firm CinCor

The takeover marks the latest push by AstraZeneca chief executive Pascal Soriot to bolster the Covid vaccine maker's pipeline of
The takeover marks the latest push by AstraZeneca chief executive Pascal Soriot to bolster the Covid vaccine maker's pipeline of new products.

Anglo-Swedish pharmaceuticals giant AstraZeneca on Monday agreed to buy US biotech company CinCor for $1.8 billion, expanding further into the field of heart and kidney drugs.

The takeover marks the latest push by Astra chief executive Pascal Soriot to bolster the COVID vaccine maker's pipeline of new products.

Massachusetts-based CinCor focuses on developing treatments for hypertension and .

Since taking the helm at AstraZeneca in 2012, Frenchman Soriot has expanded the company into lucrative cancer therapies.

The group completed a blockbuster of Alexion for $39 billion in 2021, giving it more heft in areas such as treating blood disorders.

© 2023 AFP

Citation: AstraZeneca buys US biotech firm CinCor (2023, January 9) retrieved 10 May 2024 from https://medicalxpress.com/news/2023-01-astrazeneca-buys-biotech-firm-cincor.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

AstraZeneca's Pascal Soriot: the man behind the vaccine

2 shares

Feedback to editors